Twist Bioscience Reports 23% Revenue Growth and Raises Full-Year Guidance

Details

The company also raised its full-year revenue guidance to a range of $456-$457 million, up from the previous guidance of $442-$447 million. Additionally, Twist Bioscience expects to achieve adjusted EBITDA breakeven in the fourth quarter. The company's DNA Synthesis and Protein Solutions segment saw a 39% revenue growth, while the NGS Applications segment grew by 12%. Despite the revenue growth, the company reported a net loss of $35.1 million for the quarter.

Items reported

About Twist Bioscience Corporation

Twist Bioscience Corporation is a synthetic biology and biotechnology company that develops and commercializes DNA-based products built on its proprietary silicon-based synthesis platform. Twist Bioscience Corporation’s core offerings include synthetic genes, DNA oligos, oligo pools, library preparation tools, antibody libraries, and other workflow products used in next-generation sequencing, gene editing, drug discovery, diagnostics, and research. The company serves customers across academic, pharmaceutical, biotech, industrial, and agricultural markets, providing scalable tools for applications that require precise, high-quality synthetic DNA. Its platform supports high-throughput manufacturing and a broad product portfolio that helps researchers and developers design, test, and advance biological innovation across multiple life science segments. Headquartered in South San Francisco, California, Twist Bioscience Corporation plays a specialized role in the global market for synthetic DNA and genomics-enabled research tools.